Current efforts are underway to test the combination of newer agents targeting EGFR mutations in NSCLC such as amivantamab, an EGFR-MET bispecific antibody32, and patritumab deruxtecan (HER3-DXd), an antibody-drug conjugate33, with osimertinib, as they are able to target a diverse range of resistance mechanisms. This evidence concerns the gene MET and non-small cell lung carcinoma.